Open Access
- 1 November 2026
- journal article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200660
Abstract
Background and ObjectivesA proportion of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) experience relapses, but biomarkers predicting which patients are like...Keywords
This publication has 27 references indexed in Scilit:
- Clear-positive cut off determination of flow cytometric MOG-antibody assay in Korea: Alignment with international MOGAD diagnostic standardsJournal of Neuroimmunology, 2025
- Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseJAMA Neurology, 2024
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteriaThe Lancet Neurology, 2023
- Myelin-oligodendrocyte glycoprotein antibody-associated diseaseThe Lancet Neurology, 2021
- Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody TestingJAMA Neurology, 2021
- Features of MOG required for recognition by patients with MOG antibody-associated disordersBrain, 2021
- Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)Journal of Neuroimmunology, 2020
- Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseAnnals of Neurology, 2020
- Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic SurfacesNano Letters, 2019
- Investigation of Myelin/Oligodendrocyte Glycoprotein Membrane TopologyJournal of Neurochemistry, 1996